{"nctId":"NCT00412061","briefTitle":"Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor","startDateStruct":{"date":"2006-12"},"conditions":["Carcinoid Tumor","Malignant Carcinoid Syndrome"],"count":429,"armGroups":[{"label":"Octreotide+ Everolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Octreotide","Drug: Everolimus"]},{"label":"Octreotide+ Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Octreotide","Drug: Placebo"]}],"interventions":[{"name":"Octreotide","otherNames":["Sandostatin LAR® Depot"]},{"name":"Placebo","otherNames":[]},{"name":"Everolimus","otherNames":["RAD001"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Advanced (unresectable or metastatic) carcinoid tumor\n* Confirmed low-grade or intermediate-grade neuroendocrine carcinoma\n* Documented progression of disease within 12 months prior to randomization.\n* Measurable disease determined by triphasic computer tomography (CT) scan or magnetic resonance imaging (MRI).\n\nExclusion criteria:\n\n* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.\n* Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.\n* Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, everolimus)\n* Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.\n* Severe or uncontrolled medical conditions\n* Chronic treatment with corticosteroids or other immunosuppressive agent.\n* Other primary cancer within 3 years.\n\nOther protocol-defined inclusion/exclusion criteria applied","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review","description":"Progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause. The primary analysis of PFS was based on the independent central adjudicated assessment using Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.43","spread":null},{"groupId":"OG001","value":"11.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate as Per Adjudicated Central Radiology Review Based on Response Evaluation Criteria in Solid Tumors (RECIST)","description":"The best overall response rate is defined as the percentage of patients having achieved confirmed Complete Response + Partial Response. Complete Response (CR) = at least two determinations of CR at least 4 weeks apart before progression. • Partial response (PR) = at least two determinations of PR or better at least 4 weeks apart before progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) as Per Adjudicated Central Review by Baseline 5-hydroxyindoleacetic Acid (5-HIAA) Level","description":"5-HIAA levels in urine are frequently elevated in patients with advanced carcinoid tumors. Baseline levels of 5-HIAA in urine were defined as 'High' if they exceeded the median value, and 'Low' if they were lower than or equal to the median.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.75","spread":null},{"groupId":"OG001","value":"13.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.83","spread":null},{"groupId":"OG001","value":"8.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Using Kaplan-Meier Methodology","description":"Overall survival was defined as the time from the date of randomization to the date of death from any cause. If a patient was not known to have died, survival was censored at the date of last contact. Kaplan-Meier methodology was used to estimate the median overall survival for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"48.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"41.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events (AEs), Clinically Notable AE, Death, Serious Adverse Events (SAEs) (Double-Blind Phase)","description":"AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events (AEs), Clinically Notable AE, Death, Serious Adverse Events (SAEs) (Open Label Phase)","description":"AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) as Per Adjudicated Central Review by Baseline Chromogranin A (CgA)","description":"Serum CgA levels in urine are frequently elevated in patients with advanced carcinoid tumors. Baseline levels of serum CgA were characterized relative to the upper limited of normal (ULN). CgA levels exceeding 2 x ULN were considered to be 'Elevated'; otherwise considered as \"Non-elevated\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.31","spread":null},{"groupId":"OG001","value":"20.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.93","spread":null},{"groupId":"OG001","value":"8.41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":126,"n":215},"commonTop":["Diarrhoea","Fatigue","Nausea","Oedema peripheral","Stomatitis"]}}}